Progress and Hurdles for Follow-on Biologics

In a Perspective for the New England Journal of Medicine, Sarpatwari and Kesselheim discuss the future of follow-on biologics in the United States. Among other issues, the article discusses the impact that so-called carve-outs from state drug product selection laws will have on reducing the market penetration of interchangeable biologics.